Scarica l'app Stockscreener
0.927
5.38%
-0.0527
Dopo l'orario di chiusura:
.93
0.003
+0.32%
Precedente Chiudi:
$0.9797
Aprire:
$0.98
Volume 24 ore:
4.16M
Relative Volume:
1.15
Capitalizzazione di mercato:
$58.38M
Reddito:
$233.00K
Utile/perdita netta:
$-64.61M
Rapporto P/E:
-0.8036
EPS:
-1.1536
Flusso di cassa netto:
$-58.32M
1 W Prestazione:
-14.17%
1M Prestazione:
-66.41%
6M Prestazione:
-69.00%
1 anno Prestazione:
-33.31%
Intervallo 1D:
$0.886
$1.08
Intervallo di 1 settimana:
$0.886
$1.89
Portata 52W:
$0.886
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Nome
Connect Biopharma Holdings Ltd
Settore
Industria
Telefono
858-727-1040
Indirizzo
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
0.927 | 68.01M | 233.00K | -64.61M | -58.32M | -1.1536 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Iniziato | Lake Street | Buy |
| 2025-10-31 | Iniziato | BTIG Research | Buy |
| 2025-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | Jefferies | Buy |
| 2021-04-13 | Iniziato | Piper Sandler | Overweight |
| 2021-04-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Connect Biopharma Holdings Ltd Borsa (CNTB) Ultime notizie
Why is Connect Biopharma stock surging today? - Investing.com
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views - Benzinga
Why Is Connect Biopharma Stock Trading Higher Today?Connect Biopharma Hldgs (NASDAQ:CNTB) - Benzinga
BTIG cuts Connect Biopharma stock price target on trial timeline - Investing.com
Connect Biopharma stock jumps on positive COPD trial data - Yahoo! Finance Canada
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Connect Biopharma reports positive phase 2 COPD trial results - Investing.com India
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - The Manila Times
Preliminary results at Connect Biopharma (CNTB) show fewer treatment failures but a missed lung-function target. - Stock Titan
A COPD treatment cut hospital stays and ER visits for new flare-ups by 100% vs placebo through Week 4 - Stock Titan
Connect Biopharma Holdings Limited (CNTB) Stock Price, News, Quote & History - ca.finance.yahoo.com
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView
H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 - Investing.com
Connect Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co. - Moomoo
Connect Biopharma Holdings Limited (CNTB) Stock Price | Live Quotes & Charts | NASDAQ - stockstotrade.com
Canaccord cuts Connect Biopharma stock price target on trial miss - Investing.com
Connect Biopharma (NASDAQ:CNTB) Given "Buy" Rating at BTIG Research - MarketBeat
FEV1 well done, will FDA Connect the phase II asthma dots? - BioWorld News
Why Is Connect Biopharma Stock Trading Lower on Tuesday? - Benzinga
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance - Yahoo Finance
Why is Connect Biopharma stock plunging 33% today? - Investing.com
Form 8K Connect Biopharma Holdings Ltd For: 15 September By Investing.com - Investing.com India
Connect Biopharma reports phase 2 asthma trial results By Investing.com - Investing.com India
Connect Biopharma (CNTB) asthma trial cuts failures 66% but misses main goal - Stock Titan
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation - globenewswire.com
H.C. Wainwright reiterates Connect Biopharma stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A Sept. 15 live webcast will feature Connect Biopharma management - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - simplywall.st
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
Connect Biopharma stock rating reiterated at Buy by Canaccord - Investing.com South Africa
Will Connect Biopharma (CNTB) Breathe Easy After Seabreeze Trials? - RTTNews
Connect Biopharma Holdings Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Issues Pessimistic Forecast for CNTB Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ikarian Capital (CNTB) discloses 6.9% Connect Biopharma holding on Schedule 13G/A - Stock Titan
Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake - Stock Titan
Connect Biopharma Holdings Ltd expected to post a loss of 21 cents a shareEarnings Preview - TradingView
BTIG Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Connect Biopharma Holdings earnings beat by ¥0.33, revenue topped estimates - Investing.com Canada
Connect Biopharma Holdings earnings beat by ¥0.34, revenue topped estimates - Investing.com
Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million - scanx.trade
Connect Biopharma (NASDAQ:CNTB) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Connect Biopharma (CNTB) ramps rademikibart spend as losses deepen in 2026 - Stock Titan
Connect Biopharma Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Connect Biopharma (CNTB) widens Q2 2026 loss as R&D rises, cash at $31.5M - Stock Titan
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Holdings Ltd Azioni (CNTB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Connect Biopharma Holdings Ltd Azioni (CNTB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Huang James | Director |
Mar 31 '26 |
Buy |
3.45 |
1,160,000 |
4,002,000 |
13,160,000 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):